SABCS 2023

Explore the latest advancements for enabling precision oncology as we discuss recent research findings, breakthroughs in molecular profiling, the expansion of our liquid biopsy portfolio and the impact AI-enabled technological innovations have on reshaping the advanced breast cancer landscape. Join us to gain essential insights and be a part of the evolution of personalized breast cancer patient care.

Authors Siddhartha Yadav (Mayo Clinic), Ali Arafa (University of Minnesota), Emily Teslow (Tempus), Minxuan Huang (Tempus), Melissa Stoppler (Tempus), Calvin Chao (Tempus), Emmanuel Antonarakis (University of Minnesota), Fergus Couch (Mayo Clinic)

Utilizing the Tempus multimodal real-world database, the research team assessed the landscape of somatic alterations in breast cancer patients with hereditary pathogenic variants in five DNA-repair genes compared to those with sporadic breast tumors. The observed frequencies of CCND1, ESR1, PIK3CA, FGFR1, and TP53 alterations differed between these patient groups, breast cancer subtypes, and the pathogenic hereditary gene indicating there may be underlying differences in tumorigenesis for patients with hereditary breast cancer.

Authors Rosario Chica-Parrado (UT Southwestern), Chang-Ching Lin (UT Southwestern), Ellen Jaeger (Tempus), Michelle Harris (Tempus), Lei Guo (UT Southwestern), Emmanuel Bikorimana (UT Southwestern), Fabiana Napolitano (UT Southwestern), Calvin Chao (Tempus), Ariella Hanker (UT Southwestern), Carlos Arteaga (UT Southwestern)

In order to identify if ESR1 mutations drive resistance to CDK4/6 inhibitors (CDK4/6i) in ER+/HER2- breast cancer (BC), the research team leveraged Tempus’ multimodal real-world data to stratify ER+ BC patients treated with or without a CDK4/6i. They found that ESR1 mutations were enriched in patients treated with a CDK4/6i in a cohort of 3,958 patients with ER+/HER2- metastatic BC. Additionally, the team utilized in vitro and in vivo models, along with RNA-seq, to demonstrate that known ESR1 gain-of-function mutations were sufficient to confer resistance to CDK4/6 inhibitors.

Authors Talal Ahmed (Tempus), Mark Carty (Tempus), Kaverni Nadhamuni (Tempus), Raphael Pelossof (Tempus)

The research team analyzed the Tempus multimodal real-world database to validate an RNA-seq-based, in-house breast intrinsic subtype predictor based on PAM50 subtypes including: Basal, HER2-like, Luminal A, and Luminal B. The subtype predictor demonstrated significant prognostic value in the basal-subtype across all metastatic sites examined including lymph node, liver, lung, and bones, as well as HR+/HER2- and HR-/HER2- cohorts. This work highlights the significance of combining molecular subtypes with IHC-based diagnostics to fully characterize clinically relevant subpopulations and risk.